admin

- Appointed Michael Amoroso as President and Chief Executive Officer and to Board of Directors; Sam Wadsworth , Ph.D., and Shari Lisa Piré, J.D., Appointed to Board of Directors - Hosted In Vivo Gene Editing R&D Event and Outlined Plans for Accelerated Path to Clinic for Three Investigational New

DURHAM, N.C. --(BUSINESS WIRE)--Nov. 9, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, today announced that the abstract titled, “Allogeneic CAR T

New Directors Add Decades of Cell and Gene Therapy Development and Strategic Business Growth Experience DURHAM, N.C. --(BUSINESS WIRE)--Nov. 8, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS ® genome editing platform to develop allogeneic

- Enhanced Lymphodepletion Improved Overall Response Rate and Complete Response Rate Compared to Standard Lymphodepletion in Heavily Pretreated NHL and B-ALL Subjects with a Median of ~6 Prior Lines of Therapy - Clinically Significant Activity in Subjects Previously Treated with Autologous CD19

DURHAM, N.C. --(BUSINESS WIRE)--Nov. 3, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, today announced that it will publish financial results for the

DURHAM, N.C. --(BUSINESS WIRE)--Oct. 21, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS ® genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, today announced that Derek Jantz , Ph.D., Chief Scientific

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, issued the following statement about the safety of its allogeneic CAR T cell therapies.

DURHAM, N.C. --(BUSINESS WIRE)--Sep. 27, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, today announced an inducement grant for Michael Amoroso , newly

DURHAM, N.C. --(BUSINESS WIRE)--Sep. 27, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, today announced that Michael Amoroso has been named as the

DURHAM, N.C. --(BUSINESS WIRE)--Sep. 10, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced that it will present at the H.C.

- Accelerated Clinical Development Expected to Enable Three Investigational New Drug/Clinical Trial Applications Within Next Three Years, Including for Familial Hypercholesterolemia as early as 2022, Primary Hyperoxaluria Type 1 in 2023, and Chronic Hepatitis B in 2024 - Announced Licensing and

iECURE to License Precision’s PCSK9-Directed ARCUS Nuclease and Pursue Four Gene Insertion Programs Focused on Liver Diseases; Precision Retains Rights Across All Indications Except Those Licensed to iECURE iECURE Expects to File a Clinical Trial Application as Early as 2022 for Precision’s

Precision Gains Access to Tiziana’s Anti-CD3 Antibody, Foralumab, to Evaluate as a Lymphodepletion Agent with its Allogeneic CAR T Portfolio DURHAM, N.C. , NEW YORK & LONDON --(BUSINESS WIRE)--Sep. 2, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company

DURHAM, N.C. --(BUSINESS WIRE)--Aug. 25, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced that it will host its first R&D event focused

- Presented Interim Data Showing PBCAR0191 with Enhanced Lymphodepletion Yielded Overall Response Rate of 75% and Complete Response Rate of 50% at Day ≥ 28 - Dosed First Patient in CD19-Targeted Phase 1 Clinical Trial with PBCAR19B Immune-Evading Stealth Cell - Precision to Host First In Vivo Gene